Study Details

Back to Search Results

A Study to Assess the Antitumor Activity, Safety, Pharmacokinetics and Biomarkers of Zolbetuximab (IMAB362) in Participants with Claudin (CLDN) 18.2 Positive, Metastatic or Advanced Unresectable Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma

This trial is recruiting
The study is currently recruiting participants.

Clinicaltrials.gov ID

The unique identification code given to each clinical study upon registration at ClinicalTrials.gov.
NCT03505320

Astellas Study ID

The unique identification code given by the study sponsor.

8951-CL-0103

EudraCT ID

The unique identification code given to each clinical study upon registration at EudraCT (European Union Drug Regulating Authorities Clinical Trials Database).

2017-002566-50

Follow Trial

Condition

Other, Stomach or Esophageal Cancer

Phase

These clinical trials are done to learn if an experimental treatment helps participants who have a specific condition or disease. Phase 2 trials usually include a larger group of participants than Phase 1 trials.

Phase 2

Age

18 Years - N/A

Sex

Female & Male

Product

zolbetuximab

Type

A type of clinical study in which participants are assigned to groups that receive one or more intervention/treatment (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes.

Interventional

Trial Dates

Jun 2018 - Jul 2024

Masking

Double (Participant, Investigator)

Enrollment number

116

A Phase 2 Study of Zolbetuximab (IMAB362) as Monotherapy, in combination with mFOLFOX6 (with or without Nivolumab) and in Combination with Pembrolizumab in Subjects with Metastatic or Locally Advanced Unresectable Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma whose Tumors have High or Intermediate Claudin (CLDN) 18.2 Expression

Study summary

Get More Information

Would you like more information about clinical trial sites that are recruiting participants for A Study to Assess the Antitumor Activity, Safety, Pharmacokinetics and Biomarkers of Zolbetuximab (IMAB362) in Participants with Claudin (CLDN) 18.2 Positive, Metastatic or Advanced Unresectable Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma? Contact us by filling our your information to the right and we’ll respond to you.

By clicking ["Continue/Submit"], you agree that Astellas may contact you by email with information to help you connect with clinical trial sites. While we can connect you to clinical trial sites, we cannot answer questions about any investigational therapy through email. Your consent to receiving emails is not a requirement to participate in a clinical trial or study. For more information, including how to unsubscribe at any time, see our Privacy Notice & Cookies Policy.

Locations

Site FR33002

Poitiers, France, 86021

Recruiting
Contact Us

Indiana University Cancer Center

Indianapolis, United States, 46077

Other
Contact Us

Site IT39005

Milano, Italy

Recruiting
Contact Us

Memorial Sloan Kettering Cancer Center

New York, United States, 10065

Other
Contact Us

Karmanos Cancer Institute

Detroit, United States, 48201

Other
Contact Us

UCLA Medical Center

Santa Monica, United States, 90404

Other
Contact Us

Site FR33003

Pessac, France, 33604

Recruiting
Contact Us

Site KR82002

Seongnam-si, Republic of Korea

Recruiting
Contact Us

Weill Cornell Medical College

New York, United States, 10065

Other
Contact Us

Site IT39004

Padova, Italy

Other
Contact Us

Site TW88602

Tainan, Taiwan, Province of China, 70403

Other
Contact Us

Site TW88601

Taichung, Taiwan, Province of China

Recruiting
Contact Us

The Angeles Clinic and Research Institute

Los Angeles, United States, 90025

Other
Contact Us

Site IT39003

Pisa, Italy

Other
Contact Us

University of Chicago

Chicago, United States, 60637

Recruiting
Contact Us

Sanford Cancer Center

Sioux Falls, United States, 57104

Other
Contact Us

Site FR33004

Paris, France, 75015

Recruiting
Contact Us

Site FR33001

Brest, France

Recruiting
Contact Us

Virginia Cancer Specialists

Fairfax, United States, 22031

Other
Contact Us

Site KR82001

Seoul, Republic of Korea

Recruiting
Contact Us

Site IT39002

Napoli, Italy

Other
Contact Us

Site JP81001

Chiba, Japan

Recruiting
Contact Us

Georgetown Univ Hospital

Washington, United States, 20007

Other
Contact Us

Site JP81003

Tokyo, Japan

Recruiting
Contact Us

Site JP81002

Tokyo, Japan

Recruiting
Contact Us

Mass General / North Shore Can

Boston, United States, 02114

Recruiting
Contact Us

The purpose of this website is to offer education and information to patients and their families and friends, the public, and healthcare professionals about the clinical trial process. In addition, the website will provide specific information about Astellas clinical trials. Please read the complete Astellas Transparency Policy to learn about the clinical trial information available on this website

© ASTELLAS PHARMA GLOBAL DEVELOPMENT, INC.

POWERED BY:

Pharma Intelligence logo